Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5603025 | Heart, Lung and Circulation | 2016 | 29 Pages |
Abstract
Our findings suggest that administering EPO before anaesthesia is emerging as an important factor for efficacy. Erythropoietin may have a role in preventing CSA-AKI, however, additional high-quality prospective studies are warranted, particularly aimed at describing the methodological components, such as the timing and size of the dose, which potentiate the cytoprotective effect of EPO in the clinical setting.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jahan Che BHlthSc, LLB, Andrew D. MBBS, M.Epid, MPH, FRACS, FRCS (CTh), FCSANZ, Luke A. BSc, Julian A. MBBS, MS, FRACS, FACS, FCSANZ,